- Policy
- 'BIO KOREA 2024' begins
- by Lee, Hye-Kyung May 10, 2024 05:47am
- 'BIO KOREA 2024' will be held on May 8-May10 for three days at Coex, Seoul. The conference is co-organized by the Korea Health Industry Development Institute (President Soon-do Cha, referred to as KHIDI) and Chungcheongbuk-do Province (Mayor Young Hwan Kim, referred to as Chungbuk), and sponsored by the Ministry of Health and Welfare (MOHW).
- Opinion
- [Reporter’s View] The dark side of the coveted MNC jobs
- by Eo, Yun-Ho May 10, 2024 05:47am
- Multinational pharmaceutical companies have become the wannabe companies for job seekers. With high salaries that are comparable to those of large companies and the flexible working arrangements that allow remote work, generous vacation days, generous in-house benefits, and a horizontal corporate culture, it seems anyone would jump at the ch
- Company
- Dong-A ST will exclusively supply surgical robot Versius
- by Son, Hyung-Min May 10, 2024 05:47am
- Dong-A ST announced on the 8th that it has signed an agreement with CMR Surgical for the exclusive supply and distribution of the surgical robot ‘Versius’ in Korea. Versius was developed by CMR Surgical, a British company specializing in surgical robots. It has the advantage of having small,&160;modular, and portable robot arms. It can
- Company
- 98% relapse-free Soliris is reimbursed for NMOSD in Korea
- by Son, Hyung-Min May 10, 2024 05:47am
- A new treatment option has been introduced for patients with neuromyelitis optica spectrum disorder (NMOSD), a disease that has over a 90% relapse rate. Soliris became fully reimbursable for NMOSD last month, recording a 98% relapse-free rate. However, there are concerns that the stringent reimbursement requirements for Soliris may reduce pa
- Company
- Korean AI-driven drug discovery speeds up
- by Nho, Byung Chul May 10, 2024 05:46am
- AI-driven new drug discovery through data collaboration among the biopharmaceutical industry, medical institutions, research institutions, universities, and public institutions has accelerated and gained significant attention. Previously, individual biopharmaceutical companies in South Korea conducted AI-driven new drug discovery throug
- Company
- 'Lixiana' dominates the DOAC market in KOR
- by Kim, Jin-Gu May 9, 2024 05:53am
- Daiichi Sankyo Korea’s 'Lixiana (edoxaban)' continues to dominate the market for Direct Oral Anti-Coagulant (DOAC). BMS’s 'Eliquis (apixaban)' sales have recently experienced a slowdown, and Bayer’s 'Xarelto (rivaroxaban)' prescription performance significantly dropped after the generic launch. The sales of Xarelto generic nearly cha
- Policy
- Celltrion Pharm completes localizing 3 Edarbi products
- by Lee, Hye-Kyung May 9, 2024 05:52am
- Celltrion Pharm has completed the localization of Edarbi Tab (azilsartan medoxomil potassium), a treatment for essential hypertension. On the 8th, the Ministry of Food and Drug Safety (MFDS) simultaneously withdrew and approved the authorization of Celltrion Pharm's Edarbi Tab 20mg. In December 2020, Celltrion Pharm acquired the entire
- Policy
- Name of transferred and aquired drugs can be changed in KOR
- by Lee, Hye-Kyung May 9, 2024 05:52am
- Korea’s regulations now stipulate that brand names of a drug transferred to a different company can be changed. According to industry sources on the 7th, the Ministry of Food and Drug Safety recently announced the revision of the 'Casebook for Drug Product Naming Practices (Citizen's Guide)' and announced the allowance of brand name changes.
- Policy
- AZ renews orphan drug Strensiq’s risk-sharing agreement
- by Lee, Tak-Sun May 9, 2024 05:52am
- The risk-sharing agreement (RSA) for Strensiq Inj (asfotase alfa, AZ), a treatment for hypophosphatasia, has been successfully renewed in Korea. The drug was last covered under the RSA scheme in June 2020, when it was listed for reimbursement in Korea under the Expenditure Cap Type and Refund Type RSA. According to the National Health
- Company
- Novel targeted therapy for gastric cancer 'Vyloy' may launch
- by Eo, Yun-Ho May 9, 2024 05:52am
- 'Vyloy,' a targeted therapy for gastric cancer with a novel mechanism of action, is expected to be launched in South Korea. According to industry sources, Astellas Korea has submitted an application for approval of Vyloy (zolbetuximab), a treatment for claudin 18.2 (CLDN18.2) positive, HER2-negative, unresectable, advanced, or recurrent
